All In Biotech

Drug Trial Radar · NCT04077723

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 498 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

498

Planned (sponsor's estimate)

Start

Aug 13, 2019

Primary completion

Dec 28, 2026

Study completion Dec 28, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • Englumafusp alfaDrug

    Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).

  • ObinutuzumabDrug

    A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I). A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).

  • GlofitamabDrug

    A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III

  • TocilizumabDrug

    Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nature and frequency of dose-limiting toxicities (DLTs)Time frame: 28 days in Part I and Part II
  2. Proportion of Participants with Adverse Event (AE)Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
  3. Overall Response Rate (ORR)Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
  4. Disease Control Rate (DCR)Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
  5. Duration of Response (DOR)Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination
  6. Progression-free Survival (PFS)Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination
  7. Overall Survival (OS)Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination
  8. Complete Response (CR)Time frame: Part III: Up to 9 months or up to 18 months

Locations

35 sites in 12 countries. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Pasadena, California

  • University of California San Francisco

    San Francisco, California

  • Washington University School of Medicine

    St Louis, Missouri

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • UZ Gent

    Ghent, Belgium

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Beijing Cancer Hospital

    Beijing, China

  • Shandong Cancer Hospital

    Jinan, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Aarhus Universitetshospital Skejby

    Aarhus N, Denmark

  • Rigshospitalet

    København Ø, Denmark

  • Odense Universitetshospital

    Odense C, Denmark

  • CHRU de Lille

    Lille, France

  • CHU Montpellier - Saint ELOI

    Montpellier, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • CHU DE RENNES - CHU Pontchaillou

    Rennes, France

  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale

    Naples, Campania, Italy

  • Asst Papa Giovanni Xxiii

    Bergamo, Lombardy, Italy

  • Irccs Istituto Europeo Di Oncologia (IEO)

    Milan, Lombardy, Italy

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy

  • Auckland City Hospital, Cancer and Blood Research

    Auckland, New Zealand

  • Waikato Hospital - Cancer and Blood Research Trials Unit

    Hamilton, New Zealand

  • Pusan National University Hospital

    Busan, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Univ. 12 de Octubre

    Madrid, Spain

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, Spain

  • The HOPE Clinical Trials Unit

    Leicester, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.